Allogene looks to consolidate its position
After a delay, the Alpha-3 study faces an April futility analysis.
Arvinas seeks to outdo Astellas
Early data are coming with the KRAS G12D degrader ARV-806.
Incyte’s JAK insurance policy heads for the clinic
A first-in-human trial of PRT12396 starts next month.
Merck takes Terns
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
BeOne looks to a degrader combo
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
Karyopharm gets an Xpovio blow
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
